Functional Dyspepsia
Conditions
Brief summary
This is a multicenter, randomized, double-blind, placebo-controlled dose-finding phase 2 trial to evaluate the efficacy and safety of YH12852 in patients with functional dyspepsia.
Detailed description
Eligible subjects will be randomized into one of 4 groups; YH12852 0.1 mg, 0.25 mg, 0.5 mg, or placebo at the same ratio and will be administered investigational products orally, twice daily for 4 weeks and followed up for 2 weeks.
Interventions
DRUGYH12852 0.1 mg
DRUGYH12852 0.25 mg
DRUGYH12852 0.5 mg
DRUGPlacebo
Sponsors
Yuhan Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects must be willing and able to provide written informed consent. 2. BMI of \< 35 kg/m2 3. Patients experiencing one or more of functional dyspepsia symptoms beginning at least 6 months prior according to Rome III criteria, with the symptom(s) evident over the last 3 months at the time of screening 4. Patients with no evidence of organic lesions based on upper GI endoscopy, which could be the cause of dyspeptic symptoms 5. Women of childbearing potential (WOCBP) must have a negative pregnancy test result at the screening visit and use an adequate method of contraception to avoid pregnancy throughout the study
Exclusion criteria
1. Women who are pregnant or breastfeeding. 2. Women with a positive pregnancy test result on enrollment or prior to investigational product administration. 3. Subjects with a history of surgery that could affect gastrointestinal motility 4. Subjects with inflammatory bowel disease 5. Clinically significant chronic infection (eg. AIDS, etc), or significant medical or psychiatric illness. 6. Serious cardiovascular disease (including QT prolongation defined as QTc interval ≥ 450msec) or respiratory disease 7. History of alcohol or drug abuse within the previous one year. 8. Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the inability to complete the study 9. Physical and Laboratory Test Findings 10. Administration of any other investigational product or participation in other clinical trials within 3 months prior to randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of OTE (Overall Treatment Efficacy) responders | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Ratio of OSS responders | 4 weeks |
| Elimination rate for 8 functional dyspepsia symptoms | 4 weeks |
| Change from basline in NDI QoL score | 4 weeks |
Countries
South Korea
Outcome results
None listed